Cargando…

Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation

OBJECTIVE: This study aimed to evaluate the efficacy and safety of eltrombopag (ELT) in the treatment of thrombocytopenia following hematopoietic stem cell transplantation (HSCT). MATERIALS AND METHODS: Forty-eight patients treated with ELT for thrombocytopenia after allogeneic or autologous transpl...

Descripción completa

Detalles Bibliográficos
Autores principales: Güven, Zeynep Tuğba, Çelik, Serhat, Eser, Bülent, Çetin, Mustafa, Ünal, Ali, Kaynar, Leylagül
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160700/
https://www.ncbi.nlm.nih.gov/pubmed/35297243
http://dx.doi.org/10.4274/tjh.galenos.2022.2021.0675
_version_ 1784719323741290496
author Güven, Zeynep Tuğba
Çelik, Serhat
Eser, Bülent
Çetin, Mustafa
Ünal, Ali
Kaynar, Leylagül
author_facet Güven, Zeynep Tuğba
Çelik, Serhat
Eser, Bülent
Çetin, Mustafa
Ünal, Ali
Kaynar, Leylagül
author_sort Güven, Zeynep Tuğba
collection PubMed
description OBJECTIVE: This study aimed to evaluate the efficacy and safety of eltrombopag (ELT) in the treatment of thrombocytopenia following hematopoietic stem cell transplantation (HSCT). MATERIALS AND METHODS: Forty-eight patients treated with ELT for thrombocytopenia after allogeneic or autologous transplantation at the Erciyes University Bone Marrow Transplantation Center between July 2017 and July 2021 were evaluated retrospectively. RESULTS: Forty-eight HSCT recipients were included in this study. Thirty (62.5%) patients were evaluated as having experienced delayed platelet recovery (DPR) and 18 (37.5%) patients as having experienced secondary failure of platelet recovery (SFPR). The median platelet count before ELT treatment was 13x10(9)/L (range: 3-20x10(9)/L). Twenty-three patients responded to treatment and the cumulative incidence of successful platelet recovery was 48%. Patients with both DPR and SFPR responded, but patients with DPR had a higher response rate (50% vs. 44%). The median platelet count of the 23 responding patients was 12x10(9)/L (5-19x10(9)/L) before treatment and 68x10(9)/L (52-266x10(9)/L) after treatment (p<0.0001). While the number of bone marrow megakaryocytes before treatment was adequate in 22 (46%) cases, it was decreased in 26 (54%) cases. Patients with adequate bone marrow megakaryocytes had a better response rate than those without (77% vs. 23%, p<0.0001). The group with adequate megakaryocytes responded to treatment at a median of 33 days (range: 9-174 days). Patients with decreased megakaryocytes responded at a median of 55 days (30-164 days) (p=0.002). No drug-related side effects were observed in any patients. CONCLUSION: This real-life experience demonstrates that ELT is an effective and safe treatment option for thrombocytopenia after HSCT. The adequacy of bone marrow megakaryocytes before ELT treatment was an important factor affecting response to treatment.
format Online
Article
Text
id pubmed-9160700
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-91607002022-06-16 Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation Güven, Zeynep Tuğba Çelik, Serhat Eser, Bülent Çetin, Mustafa Ünal, Ali Kaynar, Leylagül Turk J Haematol Research Article OBJECTIVE: This study aimed to evaluate the efficacy and safety of eltrombopag (ELT) in the treatment of thrombocytopenia following hematopoietic stem cell transplantation (HSCT). MATERIALS AND METHODS: Forty-eight patients treated with ELT for thrombocytopenia after allogeneic or autologous transplantation at the Erciyes University Bone Marrow Transplantation Center between July 2017 and July 2021 were evaluated retrospectively. RESULTS: Forty-eight HSCT recipients were included in this study. Thirty (62.5%) patients were evaluated as having experienced delayed platelet recovery (DPR) and 18 (37.5%) patients as having experienced secondary failure of platelet recovery (SFPR). The median platelet count before ELT treatment was 13x10(9)/L (range: 3-20x10(9)/L). Twenty-three patients responded to treatment and the cumulative incidence of successful platelet recovery was 48%. Patients with both DPR and SFPR responded, but patients with DPR had a higher response rate (50% vs. 44%). The median platelet count of the 23 responding patients was 12x10(9)/L (5-19x10(9)/L) before treatment and 68x10(9)/L (52-266x10(9)/L) after treatment (p<0.0001). While the number of bone marrow megakaryocytes before treatment was adequate in 22 (46%) cases, it was decreased in 26 (54%) cases. Patients with adequate bone marrow megakaryocytes had a better response rate than those without (77% vs. 23%, p<0.0001). The group with adequate megakaryocytes responded to treatment at a median of 33 days (range: 9-174 days). Patients with decreased megakaryocytes responded at a median of 55 days (30-164 days) (p=0.002). No drug-related side effects were observed in any patients. CONCLUSION: This real-life experience demonstrates that ELT is an effective and safe treatment option for thrombocytopenia after HSCT. The adequacy of bone marrow megakaryocytes before ELT treatment was an important factor affecting response to treatment. Galenos Publishing 2022-06 2022-06-01 /pmc/articles/PMC9160700/ /pubmed/35297243 http://dx.doi.org/10.4274/tjh.galenos.2022.2021.0675 Text en © Copyright 2022 by Turkish Society of Hematology / Turkish Journal of Hematology, Published by Galenos Publishing House. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Güven, Zeynep Tuğba
Çelik, Serhat
Eser, Bülent
Çetin, Mustafa
Ünal, Ali
Kaynar, Leylagül
Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
title Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
title_full Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
title_fullStr Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
title_full_unstemmed Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
title_short Eltrombopag for Treatment of Thrombocytopenia Following Hematopoietic Stem Cell Transplantation
title_sort eltrombopag for treatment of thrombocytopenia following hematopoietic stem cell transplantation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160700/
https://www.ncbi.nlm.nih.gov/pubmed/35297243
http://dx.doi.org/10.4274/tjh.galenos.2022.2021.0675
work_keys_str_mv AT guvenzeyneptugba eltrombopagfortreatmentofthrombocytopeniafollowinghematopoieticstemcelltransplantation
AT celikserhat eltrombopagfortreatmentofthrombocytopeniafollowinghematopoieticstemcelltransplantation
AT eserbulent eltrombopagfortreatmentofthrombocytopeniafollowinghematopoieticstemcelltransplantation
AT cetinmustafa eltrombopagfortreatmentofthrombocytopeniafollowinghematopoieticstemcelltransplantation
AT unalali eltrombopagfortreatmentofthrombocytopeniafollowinghematopoieticstemcelltransplantation
AT kaynarleylagul eltrombopagfortreatmentofthrombocytopeniafollowinghematopoieticstemcelltransplantation